Poly(ADP-ribose) polymerase inhibitor therapeutic effect: are we just scratching the surface?

Nuclear ADP-Ribosylation and Its Role in Chromatin Plasticity, Cell Differentiation, and Epigenetics

(2015) Michael O. Hottiger   Annual Review of Biochemistry

Pharmacological Inhibition of Poly(ADP-Ribose) Polymerases Improves Fitness and Mitochondrial Function in Skeletal Muscle

(2014) Eija Pirinen et al.   Cell Metabolism

Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer

(2014) Jetzabel García-Parra et al.   EUROPEAN JOURNAL OF CANCER

An update on PARP inhibitors—moving to the adjuvant setting

(2014) Amir Sonnenblick et al.   Nature Reviews Clinical Oncology

Mechanisms of resistance to therapies targeting BRCA-mutant cancers

(2013) Christopher J Lord et al.   NATURE MEDICINE

The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells

(2013) Silvana B. De Lorenzo et al.   Frontiers in Oncology

Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors

(2012) Elisabet Wahlberg et al.   NATURE BIOTECHNOLOGY

Tankyrase-targeted therapeutics: expanding opportunities in the PARP family

(2012) Jenna L. Riffell et al.   NATURE REVIEWS DRUG DISCOVERY

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

(2011) Karen A Gelmon et al.   LANCET ONCOLOGY

PARP inhibitors: New tools to protect from inflammation

(2010) Vincenzo Giansanti et al.   BIOCHEMICAL PHARMACOLOGY

Inhibition of ADP Ribosylation Prevents and Cures Helicobacter-Induced Gastric Preneoplasia

(2010) I. M. Toller et al.   CANCER RESEARCH

Toward a unified nomenclature for mammalian ADP-ribosyltransferases

(2010) Michael O. Hottiger et al.   TRENDS IN BIOCHEMICAL SCIENCES